COMMUNIQUÉS West-GlobeNewswire

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics
16/03/2024
Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a cutting-edge clinic driven by developing [...]
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
15/03/2024
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq [...]
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
15/03/2024
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “ Company ” or “ NurExone ”), a pioneering biopharmaceutical company, developing regenerative medicine [...]
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
15/03/2024
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15/03/2024
ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also [...]
Sanofi: Information concerning the total number of voting rights and shares - February 2024
15/03/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2024
15/03/2024
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.
15/03/2024
The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex’s innovative FDA approved non-opioid therapies and pipeline candidate products. The certification is [...]
Gain Therapeutics to Present at Public Ventures Discovery Day
15/03/2024
Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr. BETHESDA, [...]
Ibogaine By David Dardashti: Government Urged to Increase Funding for Quantum Electrodynamics Research
15/03/2024
Exploring the Relationship Between Glial Cells and Electromagnetic Waves MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti today announced that they are advocating to the government to increase [...]
Quantum Electrodynamics and Chaos Theory Enhance Ibogaine's Psychological Experience
15/03/2024
Ibogaine By David Dardashti applies the principles of Quantum Electrodynamics and Chaos Theory to optimize the ibogaine experience MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is introducing a [...]
Healthcare Triangle, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
15/03/2024
PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader in digital transformation solutions including managed services, [...]
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
15/03/2024
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
15/03/2024
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will [...]
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
15/03/2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
15/03/2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Sienna Announces March Dividend
15/03/2024
MARKHAM, Ontario, March 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
15/03/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a [...]
Genmab Announces Initiation of Share Buy-Back Program
15/03/2024
Company Announcement Repurchase of up to DKK 3.5 billion worth of shares Completion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is [...]

Pages